We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+4.2%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$208M
AUM Growth
-$25.1M
Cap. Flow
-$39.5M
Cap. Flow %
-18.99%
Top 10 Hldgs %
75.53%
Holding
46
New
9
Increased
5
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
CNXR
Connecture, Inc.
CNXR
+$49.4M
2
ARWR icon
Arrowhead Research
ARWR
+$7.67M
3
TOVX icon
Theriva Biologics
TOVX
+$6.14M
4
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$4.6M
5
AGEN
Agenus
AGEN
+$2.89M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$11.7M
3
AMBI
Ambit Biosciences Corp
AMBI
+$9.24M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$7.5M
5
FLNA
Filana Therapeutics
FLNA
+$7.11M

Sector Composition

Rank Sector Weight
1 Healthcare 51.88%
2 Technology 23.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNXR
1
DELISTED
Connecture, Inc.
CNXR
$49.6M 23.86%
+5,502,965
New +$49.4M
HPTX
2
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$24M 11.53%
998,066
+204,202
+26% +$4.6M
ALIM
3
DELISTED
Alimera Sciences
ALIM
$14.5M 6.99%
174,657
– –
OCRX
4
DELISTED
Ocera Therapeutics, Inc.
OCRX
$12.5M 6.02%
1,963,778
+104,463
+6% +$611K
DSCI
5
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$11M 5.31%
1,185,632
+24,028
+2% +$209K
INFI
6
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$10.6M 5.08%
625,000
-475,000
-43% -$6.92M
ELGX
7
DELISTED
Endologix Inc
ELGX
$9.94M 4.78%
65,000
-32,320
-33% -$4.03M
AUPH icon
8
Aurinia Pharmaceuticals
AUPH
$1.91B
$8.88M 4.28%
2,485,576
+11,500
+0.5% +$40.9K
ARWR icon
9
Arrowhead Research
ARWR
$11.9B
$8.32M 4%
+1,126,835
New +$7.67M
ARDM
10
DELISTED
Aradigm Corp Common Stock
ARDM
$7.62M 3.67%
1,002,962
-5,100
-0.5% -$39.8K
EBS icon
11
Emergent Biosolutions
EBS
$373M
$6.81M 3.28%
250,000
-40,000
-14% -$953K
VCEL icon
12
Vericel Corp
VCEL
$2.35B
$6.6M 3.18%
2,170,000
– –
TOVX icon
13
Theriva Biologics
TOVX
$9.64M
$5.84M 2.81%
+457
New +$6.14M
VCYT icon
14
Veracyte
VCYT
$3.7B
$5.36M 2.58%
554,426
-52,870
-9% -$413K
TENX icon
15
Tenax Therapeutics
TENX
$363M
$4.26M 2.05%
35
– –
AGEN
16
Agenus
AGEN
$312M
$3.65M 1.76%
+46,889
New +$2.89M
OFIX icon
17
Orthofix Medical
OFIX
$477M
$3.31M 1.59%
110,000
-154,873
-58% -$4.54M
EXEL icon
18
Exelixis
EXEL
$13.3B
$3.22M 1.55%
2,233,711
-2,866,289
-56% -$4.47M
ADMS
19
DELISTED
Adamas Pharmaceuticals
ADMS
$2.97M 1.43%
+170,816
New +$2.59M
FRTX
20
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$2.22M 1.07%
672
-288
-30% -$1.02M
TRAW icon
21
Traws Pharma
TRAW
$6.85M
$1.82M 0.88%
10
+4
+67% +$978K
BLCM
22
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.15M 0.55%
+5,000
New +$1.07M
NBIX icon
23
PUT
Neurocrine Biosciences
NBIX
$16.8B
$1.03M 0.5%
+46,200
New +$875K
LITS
24
Lite Strategy Inc
LITS
$32.8M
$673K 0.32%
7,883
– –
STRM
25
DELISTED
Streamline Health Solutions
STRM
$656K 0.32%
10,107
– –
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2014 Portfolio in Review

As of Q4 2014, Great Point Partners held 46 positions worth $208M, down 11% from $233M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Great Point Partners withdrew a net $39.5M in Q4 2014, closing 18 positions and reducing 9 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 71% a quarter earlier, followed by Technology.

Against the trend, Great Point Partners opened a new position in Connecture, Inc. worth $49.6M.

  • Great Point Partners's largest Q4 2014 buy was Connecture, Inc.: 5,502,965 shares worth $49.6M.
  • Great Point Partners added most to HYPERION THERAPEUTICS INC COM STK (DE) in Q4 2014, an estimated $4.6M increase.
  • Great Point Partners's biggest Q4 2014 reduction was Infinity Pharmaceuticals, Inc., cutting an estimated $6.92M.
  • Great Point Partners fully exited Neurocrine Biosciences in Q4 2014, selling an estimated $22M.
  • Great Point Partners's ten largest holdings make up 76% of its $208M portfolio in Q4 2014.
  • Great Point Partners opened 9 new positions and closed 18 in Q4 2014.
  • Great Point Partners's portfolio value fell 11% quarter-over-quarter to $208M.

Based on Great Point Partners's 13F filing for Q4 2014, filed 17 Feb 2015.